 "Glenmark receives US FDA nod for cholesterol-lowering drug fenofibrate")
Glenmark Pharmaceuticals has been granted final approval by the US Food & Drug Administration (FDA) for Fenofibrate capsule (67 mg, 134 mg and 200 mg). Fenofibrate, a drug of the fibrate class, is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease.
The approved product is the generic version of AbbVie Inc’s Tricor micronised capsule.
According to IMS Health sales data for the 12 month period ending February 2017, the Tricor micronised capsule (67 mg, 134 mg and 200 mg) market achieved annual sales of approximately $ 97.5 million.
Glenmark’s current portfolio consists of 114 products authorised for distribution in the US marketplace and approximately 64 ANDAs are pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%